LTGO NASDAQ
Latigo Biotherapeutics Inc.
1W: -1.5%
1M: +14.3%
YTD: +23.1%
$22.15
+0.61 (+2.83%)
Weekly Expected Move ±9.1%
$18
$20
$22
$24
$26
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$5.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.3B
52W Range17.22-25.93
Volume178,712
Avg Volume341,330
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEONima Farzan
Employees59
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2026-08-07
Websitelatigobio.com
1300 Rancho Conejo Boulevard, Suite 305
Thousand Oak, CA 91320
US
Thousand Oak, CA 91320
US
About Latigo Biotherapeutics Inc.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sanofi | C-Conversion | 494,800 | — | 2026-08-10 |
| Sanofi | C-Conversion | 177,978 | — | 2026-08-10 |
| Sanofi | C-Conversion | 494,800 | — | 2026-08-10 |
| Sanofi | C-Conversion | 177,978 | — | 2026-08-10 |
| 5AM Ventures VI, L.P | C-Conversion | 4,975,543 | — | 2026-08-10 |